USA flag logo/image

An Official Website of the United States Government

Development of SCP-1 to Treat Pain in the Elderly

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
65781
Program Year/Program:
2003 / STTR
Agency Tracking Number:
AG018196
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ST. CHARLES PHARMACEUTICALS
650 Poydras St, Suite 2830 New Orleans, LA 70130
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2003
Title: Development of SCP-1 to Treat Pain in the Elderly
Agency: HHS
Contract: 2R42AG018196-02A1
Award Amount: $0.00
 

Abstract:

DESCRIPTION (provided by applicant): Acetaminophen is widely used for treatment of pain and/or fever in the elderly. This dual action is sometimes contraindicated. In many instances, pain needs to be controlled without masking the symptomatic fever (e.g., fever due to infection during the postoperative period). Acetaminophen can also cause hepatotoxicity, particularly after ingestion of large doses or chronic use of smaller doses (especially in the elderly or when liver function is affected), which can lead to death. Therefore, there is a need for new more selective compounds with greater pharmacological anti-pain potency and devoid of hepatotoxic or antipyretic effect. SCP-1 is the lead compound from St Charles Pharmaceutical's series of new proprietary derivatives of acetaminophen. SCP-1 has high analgesic activity but is free from antipyretic activity and hepatotoxicity In STTR Phase I, we explored the biological properties of SCP-1 in young and old animals. SCP-1 was effective and much less toxic than acetaminophen in young and old animals, and had an attractive pharmacokinetic profile. In STTR Phase II, we will further test and develop this drug in Phase II for treating pain in the elderly where acetaminophen is contraindicated. The analgesic properties of SCP-1 will be evaluated using two pain models: the Freund's Adjuvant inflammation assay and the formalin pain assay. We also will perform mechanism-of-action and pharmacokinetic studies using radiolabeled [14C] SCP-1.

Principal Investigator:

Kenneth W. Narducy
4082238748
KNARDUCY@MSN.COM

Business Contact:

Kenneth Narducy
5045399276
KNARDUCY@MSN.COM
Small Business Information at Submission:

St. Charles Pharmaceuticals
2020 GRAVIER ST 2020 GRAVIER ST New Orleans, LA 70112

EIN/Tax ID: 721438669
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
LOUISIANA STATE UNIV-UNIV OF NEW ORLEANS
2000 Lakeshore Drive
New Orleans, LA 70148
RI Type: Nonprofit college or university